Clinical Development Drug Trials Research 
pharmaphorum
MAY 7, 2021
UK-based Small Pharma has launched on the Toronto’s TSX Venture Exchange, raising 58 million Canadian dollars (around £34m) to develop medicines based on N,N-dimethyltriptylene (DMT) to treat depression. The post Small Pharma stock market launch funds DMT-based depression drug trial appeared first on.
pharmaphorum
JANUARY 19, 2021
Sites need to be close enough for travel, and the number of site visits and trial appointments must also be manageable for people living with the complications of having little-known and rarely-researched orphan diseases. In fact, how do rare disease patients even feel about clinical trials?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
SEPTEMBER 13, 2024
Diverse clinical trials are a matter of equity and essential for the validity and reliability of research outcomes. Historically, racial and ethnically minoritized groups or populations have been excluded from clinical trials, leading to a lack of data on how different demographic subgroups respond to treatments.
Crucial Data Soutions
FEBRUARY 24, 2020
(CDS), a leading technology provider focused on data collection and clinical trial management, today announced several updates in celebration of its tenth anniversary, including the company’s latest technological development, TrialKit AI, a machine-learning API. 888) 753-4777 carley.nolan@crucialdatasolutions.com.
pharmaphorum
MAY 14, 2021
China’s Kintor Pharmaceutical has begun late-stage US clinical development of its potential COVID drug proxalutamide – but there is scepticism over the company’s claims about its research. The post Scepticism in press over Kintor’s COVID-19 US drug trial appeared first on.
pharmaphorum
DECEMBER 1, 2022
A recent survey of clinical trial professionals found that more than two-thirds of respondents (61%) believe giving patients choice will have a positive impact on clinical research, and well over half (58%) said that their organisations plan to give patients the option to choose how they participate in clinical trials moving forward.
Expert insights. Personalized for you.
98 
Let's personalize your content